Picture of LumiraDx logo

LMDXF LumiraDx Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapValue Trap

Annual cashflow statement for LumiraDx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUSPROSPECTUSPROSPECTUS20-F20-F
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-115-133-241-101-448
Depreciation
Amortisation
Non-Cash Items27.5221429.38243
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital2.7611.3-61.5-68.98.79
Change in Accounts Receivable
Change in Inventories
Change in Payable / Accrued Expenses
Cash from Operating Activities-79.5-91.8-149-135-162
Capital Expenditures-8.44-10.7-64.4-106-25
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-4.36-0.5810
Acquisition of Business
Cash from Investing Activities-12.8-11.3-64.4-106-25
Financing Cash Flow Items-9.01-3.77-12.1-31.914.3
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities25170.7237219165
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash158-31.921.8-29-32.1